Hepatic arterial chemotherapy (HAC) with oxaliplatin (OXA), leucovorin (LV) and 5-fluorouracil (5FU): A feasible and effective regimen.

被引：0
|
作者：
Del Freo, DFAA
Lombardi, M
Mambrini, A
Muttini, MP
Pennucci, MC
Sanguinetti, F
Torri, T
Cantore, M
机构：
[1] ASL 01 Massa Carrara, Dept Oncol, Carrara, Italy
[2] ASL 01 Massa Carrara, Dept Surg, Carrara, Italy
[3] ASL Massa Carrara, Dept Oncol, Carrara, Italy
[4] ASL 01 Massa Carrara, Dept Radiol, Carrara, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] AN INTERMITTENT LEUCOVORIN CALCIUM (LV) 5-FLUOROURACIL (5FU) REGIMEN FOR ADVANCED ADENOCARCINOMA OF THE COLON
    BRUCKNER, HW
    HART, R
    SPIGELMAN, M
    FEUER, R
    HOLLAND, JF
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 202 - 202
  • [2] Oxaliplatin (OXA), 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced or metastatic gastric cancer (A/MGC).
    Cavanna, L
    Zaniboni, A
    Artioli, F
    Lazzaro, A
    Rizzi, A
    Mazzocchi, M
    Bernuzzi, P
    Bertè, R
    Bidin, L
    Palladino, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 330S - 330S
  • [3] Third line oxaliplatin with leucovorin (LV) and continuous infusion 5-fluorouracil (5FU) in metastatic colorectal cancer.
    Abón, G
    Muñoz, A
    Rubio, I
    Mañé, JM
    Ferreiro, J
    Fernández, R
    Fuente, N
    López-Argumedo, G
    Barceló, R
    Vivanco, GL
    ANNALS OF ONCOLOGY, 2000, 11 : 48 - 49
  • [4] A simplified bi-monthly regimen with leucovorin (LV) and 5-Fluorouracil (5FU) for metastatic colorectal cancer (MCRC)
    Tournigand, C
    de Gramont, A
    Louvet, C
    Andre, T
    Carola, E
    Gilles-Amar, V
    Maindrault-Goebel, F
    Lotz, JP
    Molitor, JL
    ANNALS OF ONCOLOGY, 1998, 9 : 40 - 40
  • [5] Does the dose of leucovorin (LV) matter with 5-fluorouracil (5FU) in colorectal cancer (CRC)?
    Biagi, James Joseph
    Coakley, Nadia
    Earle, Craig
    Erlichman, Charles
    Fields, Anthony L. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [6] PHARMACOKINETICS OF A NOVEL FORMULATION OF 5-FLUOROURACIL (5FU) AND LEUCOVORIN (LV): (DEFLEXIFOL) IN A PHASE I TRIAL
    Ackland, Stephen
    Garg, Madhu
    Ranson, Marie
    Jokela, Rebecca
    Reynolds, Gemma
    De Souza, Paul
    Clingan, Philip
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 21 - 22
  • [7] Oxaliplatin (L-OHP) in combination with leucovorin (LV) and 5-fluorouracil (5FU) in pretreated metastatic colorectal cancer (CRC) patients (PTS).
    Di Stefano, A
    Calandri, C
    Benedetti, G
    Poggi, B
    Mazzoni, F
    Marrocolo, F
    Spagnuolo, P
    Rimondini, S
    Crinò, L
    ANNALS OF ONCOLOGY, 2000, 11 : 68 - 68
  • [8] A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma
    Gennatas, C.
    Papaxoinis, G.
    Michalaki, V.
    Mouratidou, D.
    Andreadis, Ch.
    Tsavaris, N.
    Pafiti, A.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 (05) : 538 - 544
  • [9] Proteomics analysis of the effect of fluorouracil (5FU) and 5FU/leucovorin (LV) on colorectal cancer (CRC) in patients
    Smid, Kees
    Meijer, Erik
    Pham, Thang V.
    de Reus, Inge
    Piersma, Sander R.
    Peters, Godefridus J.
    Jimenez, Connie R.
    CANCER RESEARCH, 2015, 75
  • [10] FLUOROURACIL/LEUCOVORIN (5FU/LV) COMBINED WITH IRINOTECAN AND OXALIPLATIN (FOLFIRINOX) AS SECOND LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC PANCREATIC ADENOCARCINOMA
    Assaf, E.
    Verlinde-Carvalho, M.
    Delbaldo, C.
    Grenier, J.
    Sellam, Z.
    Pouessel, D.
    Sobhani, I.
    Tayyar, C.
    Paul, M.
    Culine, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 233 - 233
12345